2. Search Result
Search Result
Results for "

quinazoline compound

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13427
    Allitinib tosylate
    2 Publications Verification

    AST-1306 (TsOH)

    		 EGFR Cancer
    Allitinib tosylate (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. Allitinib tosylate also inhibits ErbB4 with an IC50 of 0.8 nM. Allitinib tosylate is an anilino-quinazoline compound and has anti-cancer activity
    Allitinib tosylate
  • HY-15375
    Allitinib
    2 Publications Verification

    AST-1306; ALS 1306

    		 EGFR Cancer
    Allitinib (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. Allitinib also inhibits ErbB4 with an IC50 of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity .
    Allitinib
  • HY-108419
    WHI-P258

    		JNK Cancer
    WHI-P258, a quinazoline compound, binds to the active site of JAK3 with an estimated Ki of 72 µM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM .
    WHI-P258
  • HY-156287
    GCase modulator-1

    		Glycosidase Cancer
    GCase modulator-1 (compound 9g), a derivative of Quinazoline, is a modulator of GCase (Glucosidase) (AC50=2.23 μM) .
    GCase modulator-1
  • HY-W014967
    5-Bromoanthranilonitrile

    		Biochemical Assay Reagents Others
    5-Bromoanthranilonitrile is an organic compound that reacts with sodium hydride in dimethyl sulfoxide to produce a 4-amino-2-(2-aminophenyl)quinazoline analogue .
    5-Bromoanthranilonitrile
  • HY-W007977
    4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline

    		Drug Intermediate Cancer
    4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline (Compound 11 and 15) is a building block and synthetic intermediate, which can be used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer agents. 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline can also be used to synthesize EGFR inhibitors, including Erlotinib (HY-50896), with antiproliferative activity .
    4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline
  • HY-163524
    NAE-IN-2

    		Apoptosis Cancer
    NAE-IN-2 (compound III-26) is N2–(1-benzylpiperidin-4-yl)quinazoline-2,4-diamine derivative, and inhibits Cullin1 and Cullin3. NAE-IN-2 inhibits migration and induces cell apoptosis of gastric cancer cells .
    NAE-IN-2
  • HY-156020
    Glucocerebrosidase-IN-2

    		Glycosidase Metabolic Disease
    Glucocerebrosidase-IN-2 (compound 12) is a quinazoline analogue and an inhibitor of glucocerebrosidase (GC). Glucocerebrosidase-IN-2 has the potential to improve GC translocation to lysosomes in Gaucher disease patient-derived cells (mostly carrying the N370S mutation). Glucocerebrosidase-IN-2 inhibits the hydrolysis of 4-methylumbelliferone β-D-glucopyranoside (4MU) and fluorescent glycosylceramide (FlourGC) in N370S mutant tissues with an AC50 of 25.29 μM .
    Glucocerebrosidase-IN-2
  • HY-156149
    CYP51/PD-L1-IN-1

    		Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
    CYP51/PD-L1-IN-1
  • HY-156150
    CYP51/PD-L1-IN-2

    		Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
    CYP51/PD-L1-IN-2
  • HY-156151
    CYP51/PD-L1-IN-3

    		Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
    CYP51/PD-L1-IN-3
  • HY-161512
    hAChE/hBACE-1-IN-4

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    hAChE/hBACE-1-IN-4 (compound AK-2) is a quinazoline derivative. hAChE/hBACE-1-IN-4 shows significant inhibitory activity against hAChE and hBACE-1 enzymes (hAChE, IC50=0.283 μM; hBACE-1, IC50=0.231 μM). hAChE/hBACE-1-IN-4 has the potential to inhibit Aβ aggregation. hAChE/hBACE-1-IN-4 has non-neurotoxicity , blood-brain barrier permeability and oral activity. hAChE/hBACE-1-IN-4 can be used in Alzheimer's disease research .
    hAChE/hBACE-1-IN-4
  • HY-175974
    Antitrypanosomal agent 27

    		Parasite Infection
    Antitrypanosomal agent 27 (Compound 5c) is a quinazoline compound with antitrypanosomal activity. Antitrypanosomal agent 27 inhibits T.b. brucei with a GI50 of 31 nM. Antitrypanosomal agent 27 can be used for the research of human african trypanosomiasis .
    Antitrypanosomal agent 27
  • HY-108419R
    WHI-P258 (Standard)

    		Reference Standards JNK Cancer
    WHI-P258 (Standard) is the analytical standard of WHI-P258 (HY-108419). This product is intended for research and analytical applications. WHI-P258, a quinazoline compound, binds to the active site of JAK3 with an estimated Ki of 72 µM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM .
    WHI-P258 (Standard)
  • HY-184359
    RAS GTPase-IN-2

    		Ras Metabolic Disease Inflammation/Immunology Cancer
    RAS GTPase-IN-2 is a RAS GTPase inhibitor. RAS GTPase-IN-2 can be used in the research of cancer, ras-related autoimmune leukocytosis and certain types of mitochondrial dysfunction .
    RAS GTPase-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: